Document:

EX-10.30

 Exhibit 10.30 

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY 

OF THE BOARD OF DIRECTORS 

OF 
 ROCKLEY PHOTONICS
HOLDINGS LIMITED 
 Non-employee members of the board of directors (the “Board”) of Rockley
Photonics Holdings Limited (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (“Policy”).
This Policy will be effective upon the closing of the business combination by and among SC Health Corporation, Rockley Photonics Limited, Rockley Mergersub Limited and the Company, and shall apply with respect to services rendered following such
date. The cash compensation and equity grants described in this Policy shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or
subsidiary of the Company (each, a “Non-Employee Director”), unless such Non-Employee Director declines the receipt of such cash compensation or equity
grants by written notice to the Company. This Policy shall remain in effect until it is revised or rescinded by further action of the Board. The terms and conditions of this Policy shall supersede any prior cash or equity compensation arrangements
between the Company and its directors. 
 Annual Cash Compensation 

Commencing at the beginning of the first calendar quarter following the effective date of this Policy, each
Non-Employee Director will receive the cash compensation set forth below for service on the Board. The annual cash compensation amounts will be payable in arrears following the end of each quarter in which the
service occurred, pro-rated for any partial months of service. All annual cash fees are vested upon payment. 

Annual Cash Retainer for Board Service 
  

	 	•	 	 All Non-Employee Directors: $45,000 

 

	 	•	 	 Lead Director: $23,000 (premium in addition to above) 

Annual Cash Retainer for Committee Service 
 In addition,
a Non-Employee Director shall be eligible to receive the following additional annual cash retainers for service in the following roles: 

Committee Chair: 
  

	 	•	 	 Audit: $20,000 

  

	 	•	 	 Compensation: $15,000 

  

	 	•	 	 Nominating and Corporate Governance: $10,000 

Committee Member: 
  

	 	•	 	 Audit: $10,000 

  

	 	•	 	 Compensation: $7,500 

  

	 	•	 	 Nominating and Corporate Governance: $5,000 

 

 Equity Compensation 

Non-Employee Directors shall be granted the following restricted stock unit (“RSU”) awards under the
Company’s 2021 Stock Incentive Plan or its successor (the “Plan”): 
 Annual Awards: On the first business day following the
conclusion of each regular annual meeting of the Company’s shareholders, commencing with the 2022 annual meeting, each Non-Employee Director who will continue serving as a member of the Board thereafter
shall receive a grant of RSUs (“Annual RSU Award”) under the Plan with respect to a number of shares of common stock having an aggregate fair market value as determined under the Plan equal to $162,000 calculated on the date of
grant. In addition, if a Non-Employee Director is elected to the Board after the 2022 annual meeting of shareholders and other than at an annual meeting of shareholders, the
Non-Employee Director shall receive an Annual RSU Award upon election to the Board that is prorated based upon the number of calendar days remaining before (1) the next annual meeting of shareholders, if
scheduled, or (2) the date of the first anniversary of the last annual meeting of shareholders, if the next annual meeting is not yet scheduled. 

Each Annual RSU Award shall become fully vested, subject to the applicable Non-Employee Director’s
continued service as a director, on the earliest of the 12-month anniversary of the date of grant, the next annual meeting of shareholders following the date of grant or the consummation of a Change in Control
(as defined in the Plan). 
 Initial Awards: Except as provided below, each Non-Employee Director who first
joins the Board on or after the effective date of this Policy and who was not previously an employee of the Company or a parent or subsidiary thereof shall receive a grant of RSUs (“Initial RSU Award”) under the Plan on the date of
his or her election to the Board with respect to a number of shares of common stock having an aggregate fair market value as determined under the Plan equal to $220,000 calculated on the date of grant. Subject to the applicable Non-Employee Director’s continued service as a director, the Initial RSU Award shall initially vest as to 1/3 of the total number of shares subject to the award on the earlier of the first anniversary of the
date of grant or the next annual meeting of the Company’s shareholders, and in each of the next two calendar years following the year of the initial vesting date, 1/3 of the total number of shares shall vest on the earlier of the 12-month anniversary of the prior annual meeting of shareholders or the current year annual meeting of shareholders. Notwithstanding the foregoing, each Initial RSU Award shall become 100% vested if a Change in
Control as defined in the Plan occurs during such Non-Employee Director’s service. 
 Each Non-Employee Director who joins the Board before the effective date of this Policy but will continue serving as a member of the Board thereafter will be treated for purposes of this Policy as having first joined the
Board on the effective date of this Policy and shall therefore be eligible for an Initial RSU Award. 
 Each
Non-Employee Director who is eligible for an Initial RSU Award but who joins the Board prior to the date that the RSUs have been registered under applicable U.S. securities laws will not receive the grant
until such registration is effective, and such grant shall be subject to the Non-Employee Director’s continued service through such date of grant. However, for purposes of determining the number of shares
of common stock subject to such Initial RSU Award and the applicable vesting schedule, the date on which the Non-Employee Director joins the Board (or if later, the effective date of this Policy) shall be
treated as the date of grant of the award. 

  
 2 

 The RSUs shall be subject to the terms and conditions of the Plan (including the annual limits on non-employee director grants set forth in the Plan) and an RSU agreement, including attached exhibits, in substantially the same form approved by the Board for employee grants subject to the terms specified above.

 Each Non-Employee Director may elect to defer 100% of their RSUs subject to the terms of a deferral program
approved by the Board. 
 The Board may also approve other equity grants to Non-Employee Directors under the Plan in
addition to or lieu of grants described in this Policy. 
 Expenses 

The Company shall reimburse directors for reasonable and customary
out-of-pocket expenses incurred by the directors in attending board and committee meetings and otherwise performing their duties and obligations as directors. 

  
 3Exhibit 10.1

 

CONSULTING
AND SCIENTIFIC ADVISORY BOARD AGREEMENT

 

This
Agreement, dated as of April 13, 2021, is made and entered into by and between Cocrystal Discovery, Inc., a Delaware corporation (the
“Company”) and Roger Kornberg, an individual whose principal residence is in California (“Advisor”).

 

1. Services

 

1.1 Scope
of Services. During the Term (as defined below), Advisor will serve as a consultant to the Company and chairman of the Company’s
Scientific Advisory Board (“SAB”).of Cocrystal Pharma, Inc., the Company’s parent. In connection therewith, Advisor
will, as reasonably requested by the Company:

 

(a) meet
with other SAB members and employees of the Company to review the goals of the Company and develop strategies for achieving them;

 

(b) provide
advice, feedback, theories, techniques and improvements for the Company’s research and product development programs;

 

(c) provide
advice and observations regarding drug issues, including, but not limited to, feasibility, clinical need, economics and regulatory effects
and requirements;

 

(d) provide
suggestions for new potential clinical indications and research opportunities for the Company;

 

(e) provide
advice for and participate in the recruitment of the Company’s scientific staff; and

 

(f) perform
such duties that are established by mutual agreement of the Company and its SAB members.

 

Advisor
will perform the foregoing services (“Services”) faithfully, diligently and to the best of Advisor’s skill and ability.

 

1.2 Meetings.
Advisor will (a) attend at least one SAB meeting in person each calendar year at a location specified by the Company, and (b) participate
in a reasonable number of other SAB meetings by telephone. All SAB meetings will be scheduled by mutual agreement of the Company and
the members of the SAB.

 

1.3 Time
Commitment. The parties presently estimate that Advisor will be spending approximately 6 days per calendar year (full time equivalent)
in providing the Services. If travel time to attend meetings adds significantly to the overall time spent on the Company’s matters,
such travel time will be separately addressed by the parties.

 

1.4 Relationship
of the Parties. Advisor is an independent contractor, not an employee or agent, of the Company. Advisor has no authority to obligate
the Company by contract or otherwise. Advisor will not be eligible for any employee benefits. The Company will not make deductions from
any amounts payable to Advisor for taxes. Advisor will be responsible for and will pay all taxes related to the receipt of payments hereunder
and will give reasonable proof in supporting documents, if reasonably requested, to verify the payment of such taxes.

 

    	1

    	 

    

 

2. Compensation
and Payment

 

2.1 Retainer.
The Company will pay Advisor an annual cash retainer of $75,000 (the “Retainer”), paid quarterly in arrears, in consideration
for Advisor’s performance of the Services.

 

2.2 Reimbursable
Expenses. The Company will reimburse Advisor for reasonable travel and other out-of-pocket expenses incurred by Advisor in providing
the Services, which expenses have been approved in advance by the Company. In accordance with the Company’s reimbursement policies,
Advisor will provide to the Company an itemized expense voucher, together with receipts or other reasonable evidence or substantiation
of expenses.

 

2.3 Invoices
and Payment. Advisor will promptly submit invoices for amounts payable under Section 2.1 and for reimbursable expenses under Section
2.2. The Company will pay the amount properly due and payable under each of Advisor’s invoices within thirty (30) days after the
Company’s receipt and validation of a properly submitted and correct invoice.

 

3. Proprietary
Rights and Nondisclosure

 

3.1 Advisor
recognizes that Advisor will be exposed to, have access to and be engaged in the development of information (including all tangible and
intangible manifestations) regarding the business, technology and intellectual property of the Company and Cocrystal Pharma, Inc., the
Company’s parent. All of this information, except information that (a) is the subject of a patent, patent application, copyright,
trademark or trade secret owned by Advisor before the date of this Agreement and not conveyed or licensed to the Company, (b) is in the
public domain before the date of this Agreement or comes into the public domain after the date of this Agreement through no fault of
Advisor or (c) is received by Advisor without an obligation of confidentiality from an unrelated third party that is not under an obligation
of confidentiality to the Company and that has a legal right to disclose it, is collectively referred to as the “Proprietary Information.”

 

3.2 During
the Term and thereafter, Advisor will keep in confidence and trust all Proprietary Information and will not use or disclose any Proprietary
Information or anything related thereto to any third party without the prior written consent of the Company, except as required in performing
the Services.

 

3.3 If
Advisor is required to disclose any Inventions (as defined in Section 3.5) to any research or academic institution with which Advisor
is affiliated pursuant to its applicable guidelines or policies, Advisor will notify the Company in writing and specify the nature of
such disclosure 30 days before making such disclosure. Advisor represents and warrants that Advisor has no such disclosure obligations
to any research or academic institution with which Advisor is affiliated, except as noted and described in Schedule A. Upon request,
Advisor will provide the Company with copies of any such applicable guidelines or policies.

 

    	2

    	 

    

 

3.4 Advisor
will submit to the Company any proposed publication (written or oral) that contains any discussion relating to the Company, the
Services or the Proprietary Information. Advisor will not publish, submit for publication or make an oral presentation of the
proposed publication without the Company’s prior written consent.

 

3.5
Advisor will promptly disclose to the Company in writing any and all inventions, developments or materials, whether or not patentable
or registerable under copyright or similar statutes, authored, made or conceived of or reduced to practice or learned by Advisor, either
alone or jointly with others, during the Term in the course of or as a result of performing the Services (“Inventions”).
Advisor hereby assigns to the Company for no additional consideration Advisor’s entire right, title and interest in and to the
Inventions (and all proprietary rights with respect thereto). Advisor will execute all documents and perform all acts, at the Company’s
expense, reasonably necessary to pursue, prosecute, maintain, enforce and defend any patents, patent applications, copyrights, trademarks
and other rights to the Inventions.

 

3.6 For
purposes of this Agreement, any copyrightable work authored in the course of performance of the Services under this Agreement will be
deemed “work made for hire” under federal copyright law, and all ownership rights to such work belong and are hereby assigned
to the Company.

 

4. Nondisclosure
of Third-Party Information

 

Advisor
understands that the Company has received and will receive from third parties information that is confidential or proprietary (“Third-Party
Information”) and that is subject to restrictions on the Company regarding its use and disclosure. During the Term and thereafter,
Advisor will hold the Third-Party Information in confidence and will not disclose or use Third-Party Information except as permitted
by the agreement between the Company and the relevant third party, unless expressly authorized in writing to act otherwise by an officer
of the Company.

 

5. Prior
Inventions

 

Inventions,
if any, patented or unpatented, that Advisor made before the date of this Agreement are excluded from the scope of this Agreement, except
to the extent they are unpatented and disclosed to the Company without an explicit limitation on use or, whether or not patented, included
in the work furnished to the Company by Advisor.

 

    	3

    	 

    

 

6. Representations,
Warranties, and Covenants

 

Advisor
represents and warrants to the Company that (a) Advisor’s performance of this Agreement and the Services does not and will not
breach or conflict with any agreement to which Advisor is or becomes a party, and that Advisor has obtained any and all necessary approvals
or consents necessary to perform Advisor’s obligations hereunder, (b) Advisor is not required to disclose any Inventions to any
third party pursuant to any agreement except as noted and described in Schedule A, (c) Advisor is not currently providing services in
the field of structure-based antiviral drug discovery (“Field”) to any other entity and is not an officer, employee or investor
(direct or indirect) in any other company engaged in the Field except as set forth in Schedule A, (d) Advisor will not perform
services in the Field for any other entity or be an officer, employee or investor (direct or indirect) in any other entity engaged in
the Field during the Term without advising the Company of the name of such entity and the nature of the services to be provided prior
to or within 10 days following commencement of such services, (e) during the Term and for one year after the expiration or termination
of the Agreement, Advisor will not personally or through others recruit, solicit or induce any employee, advisor, consultant, corporate
partner, supplier or customer of the Company to terminate their relationship with the Company, (f) Advisor will comply with all federal,
state and local laws applicable to the performance of the Services under this Agreement, (g) all Services will be performed in a timely,
workmanlike manner and with professional diligence and skill in accordance with the terms of this Agreement, (h) Advisor will not knowingly
infringe or misappropriate the rights of any third party in the performance of this Agreement or the Services, and (i) Advisor has received
information about the Company and is knowledgeable about the Company and its scientific business plan.

 

7. Term
and Termination

 

7.1 Term.
Unless sooner terminated or extended pursuant to this Section 7, the term of this Agreement will terminate three years from the date
of this Agreement (“Term”), and may be renewed by mutual agreement of the parties; provided, however, that this Agreement
may be terminated by either party for any reason upon thirty days prior written notice without further obligation or liability.

 

7.2 Termination.
Either party may terminate the Term upon ten (10) days’ written notice.

 

7.3 Effect
of Termination. The obligations set forth in Sections 3 through 8 will survive any termination of the Agreement. Upon expiration
or termination of the Agreement or at any other time upon request, Advisor will promptly deliver to the Company all documents and other
materials of any nature (and all copies thereof) pertaining to the Services, together with all documents and other items (and all copies
thereof) containing or pertaining to any Proprietary Information, and will not retain copies of any such documents, materials or items.

 

8. Miscellaneous.

 

8.1 Notices.
All notices given hereunder will be given in writing, will refer to this Agreement and will be personally delivered, sent by registered
or certified mail (return receipt requested), or by e-mail to the intended recipient at the appropriate e-mail address as follows:

 

If
to the Company:

 

Cocrystal
Pharma, Inc.

19805
North Creek Road

Bothell,
WA 98011

Attn:
Sam Lee

	Email:		 

 

    	4

    	 

    

 

With
a copy to:

 

Cocrystal
Pharma, Inc.

4400
Biscayne Blvd

Miami,
FL 33137

Attn:
Jim Martin

	Email:		 

 

	 	 	 
	 	 	 
	If
to Advisor:	Roger Kornberg	 
	 		 
	 		 
	 	 	 
	Email:		 
	 	 	 

 

Either
party may change such address by giving the other party notice of such change in accordance with this Section 8.1.

 

8.2 Assignment.
The parties’ rights and obligations under this Agreement will bind and inure to the benefit of their respective successors,
heirs, executors, administrators and permitted assigns. Because the nature of the Services is personal, no assignment of Advisor’s
rights or delegation of Advisor’s duties under this Agreement (by contract, operation of law, or otherwise) may be made and any
attempted assignment or delegation by Advisor will be void, without the prior written consent of the Company.

 

8.3 Governing
Law. This Agreement is governed by the laws of the state of Washington (regardless of its choice-of-law provisions to the contrary).
Advisor irrevocably consents to the jurisdiction and venue of the state and federal courts located in King County, Washington in connection
with any action relating to this Agreement.

 

8.4 Severability.
If any provision of this Agreement is held to be invalid or unenforceable to any extent, this Agreement will continue in full force
and effect and such provision will be deemed amended to conform to applicable laws and to accomplish the intentions of the parties.

 

8.5 Waiver.
Any waiver, modification or amendment of any provision of this Agreement will be effective only if in writing and signed by the parties
to this Agreement.

 

8.6 Entire
Agreement. This Agreement constitutes the parties’ final, exclusive and complete understanding and agreement with respect to
the subject matter hereof, and supersedes all prior and contemporaneous understandings and agreements relating to the subject matter
hereof.

The
parties hereto have executed this Agreement as of the date first above written.

  

	COMPANY	 	ADVISOR
	 	 	 	
	By:	/s/
    Jim Martin	 	/s/
    Roger Kornberg
	 	 	 	Roger
Kornberg
	Print:	Jim
    Martin	 	 
	Title:	CFO/Secretary	 	 

  

    	5

    	 

    

  

Schedule
A

 

    	6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]